Lawsuits against GLP-1 drugmakers surge over alleged failure to warn about serious side effects
Thousands of lawsuits have been filed against makers of blockbuster GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound
Plaintiffs allege drugmakers failed to adequately warn consumers and doctors about risks including stomach paralysis, intestinal blockages and possible vision loss
A rapidly expanding wave of lawsuits against makers of popular GLP-1 drugs is putting new scrutiny on whether consumers were adequately warned about potentially serious side effects tied to the blockbuster diabetes and weight-loss medications.
The litigation targets products including Novo Nordisk’s Ozempic and Wegovy and Eli Lilly and Company’s Mounjaro and Zepbound — drugs that have transformed the obesity and diabetes markets while generating billions in sales.
Most of the lawsuits center on allegations that manufacturers failed to properly disclose or emphasize severe gastrointestinal complications allegedly linked to the medications, including gastroparesis, also known as stomach paralysis.
Plaintiffs claim they suffered debilitating nausea, vomiting, dehydration, malnutrition, intestinal blockages and repeated hospitalizations after taking the drugs. Some lawsuits allege the injuries became permanent.
Other cases focus on reports of sudden vision loss tied to a condition known as non-arteritic anterior ischemic optic neuropathy, or NAION, sometimes described as an “eye stroke.”
The lawsuits generally argue that consumers and physicians were not adequately warned about the severity or potential permanence of the risks.
Thousands of cases consolidated
Many of the federal lawsuits have been consolidated into multidistrict litigation in federal court in Pennsylvania, where the number of cases has continued to climb.
Legal filings and court records indicate that the litigation has grown into one of the largest emerging pharmaceutical mass torts in the country, with additional lawsuits expected as awareness of the alleged injuries spreads.
Attorneys representing plaintiffs argue that stronger warnings could have changed prescribing decisions or prompted consumers to seek treatment earlier.
“This litigation is fundamentally about informed consent,” several complaints argue in varying language. “Patients cannot weigh risks they were never clearly told about.”
A more detailed version of this story is available at ConsumerNews.ai
Drugmakers defend products
Drugmakers have strongly defended the medications, noting that gastrointestinal side effects are already disclosed in prescribing information and that regulators approved the drugs after extensive clinical testing.
The companies also point to growing evidence that GLP-1 medications can reduce risks associated with obesity, diabetes and cardiovascular disease.
Researchers caution that some of the newer safety concerns remain under investigation and that observational studies do not necessarily prove the drugs directly caused the injuries alleged in the lawsuits.
At the same time, regulators in the United States and Europe continue to monitor reports involving gastrointestinal complications and vision-related adverse events.
Consumer concerns growing
The lawsuits come amid explosive demand for GLP-1 drugs, which have become some of the most prescribed and heavily advertised medications in the country.
Consumer advocates say the litigation highlights broader concerns about direct-to-consumer pharmaceutical marketing and whether patients fully understand the risks associated with newer classes of drugs.
For consumers currently taking GLP-1 medications, experts say patients should not abruptly stop treatment without consulting a physician. But they also recommend discussing persistent gastrointestinal symptoms, severe abdominal pain or sudden vision changes with a healthcare provider immediately.
What consumers should watch for
Patients taking GLP-1 drugs are being urged to seek medical attention if they experience:
Persistent vomiting or nausea
Severe abdominal pain
Inability to keep food down
Symptoms of intestinal blockage
Sudden vision changes or partial vision loss
Signs of dehydration or malnutrition
Health experts say consumers should also review medication guides carefully and report suspected side effects to the FDA’s MedWatch adverse event reporting system.